Nuveen LLC Buys New Shares in C4 Therapeutics, Inc. $CCCC

Key Points

• Nuveen LLC acquired a new stake in C4 Therapeutics by purchasing 192,424 shares valued at approximately $308,000, representing about 0.27% of the company's stock.
• Institutional investors collectively own 78.81% of C4 Therapeutics, with firms like Wells Fargo and Jane Street Group increasing their stake significantly in recent quarters.
• Wall Street analysts have mixed opinions on C4 Therapeutics, with ratings ranging from "sell" to "buy," and an average price target set at $8.00.

Nuveen LLC bought a new position in C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The fund bought 192,424 shares of the company's stock, valued at approximately $308,000. Nuveen LLC owned 0.27% of C4 Therapeutics at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. XTX Topco Ltd bought a new stake in C4 Therapeutics in the 1st quarter worth approximately $64,000. Delta Investment Management LLC bought a new stake in C4 Therapeutics in the 4th quarter worth approximately $72,000. ProShare Advisors LLC grew its position in C4 Therapeutics by 83.1% in the 4th quarter. ProShare Advisors LLC now owns 20,283 shares of the company's stock worth $73,000 after purchasing an additional 9,204 shares during the period. Deutsche Bank AG bought a new stake in C4 Therapeutics in the 1st quarter worth approximately $74,000. Finally, Lazard Asset Management LLC bought a new stake in C4 Therapeutics in the 4th quarter worth approximately $81,000. Institutional investors own 78.81% of the company's stock.

C4 Therapeutics Stock Performance

Shares of C4 Therapeutics stock traded up $0.09 on Thursday, hitting $2.73. 849,200 shares of the company's stock were exchanged, compared to its average volume of 1,040,881. The company has a 50-day simple moving average of $2.34 and a 200-day simple moving average of $1.89. The stock has a market capitalization of $194.29 million, a PE ratio of -1.73 and a beta of 2.98. C4 Therapeutics, Inc. has a 1 year low of $1.09 and a 1 year high of $7.22.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.01. C4 Therapeutics had a negative net margin of 325.88% and a negative return on equity of 53.91%. The business had revenue of $6.46 million for the quarter, compared to analysts' expectations of $5.24 million. On average, analysts expect that C4 Therapeutics, Inc. will post -1.52 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CCCC has been the subject of a number of research analyst reports. Guggenheim initiated coverage on shares of C4 Therapeutics in a research report on Wednesday, September 3rd. They issued a "buy" rating and a $8.00 target price for the company. Zacks Research cut shares of C4 Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, August 22nd. Finally, Wall Street Zen cut shares of C4 Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Two analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $8.00.

C4 Therapeutics Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.